Warfarin monitoring aims to stabilise a patient’s international normalised ratio (INR) within set limits to help prevent serious side effects, while maximising effective treatment. This document contains recommendations for best practice in relation to the monitoring of warfarin therapy in Wales.
|
This resource has been retired and is no longer considered an AWMSG-endorsed resource. The resource underwent an assessment for review in June 2024. At that time members of the All Wales Prescribing Advisory Group (AWPAG) considered it appropriate to retire the resource. The content contained within the resource was considered to be out of date and, as suitable alternative guidance is available (e.g. AWMSG, SPS and NICE), AWPAG members considered it most appropriate for the resource to be retired at this time. If you think this resource should be reconsidered for review, please get in touch with AWTTC by emailing awttc@nhs.wales.uk. |
⇩ Warfarin Monitoring 622KB (PDF) |
(June 2012)
(Retired - January 2025)